{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T04:13:39Z","timestamp":1728965619903},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T00:00:00Z","timestamp":1438128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T00:00:00Z","timestamp":1438128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>We previously reported that low ratio of osteoprotegerin (OPG) to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was associated with Disease Activity Score in 28 joints (DAS28) remission at 6 months in patients with early rheumatoid arthritis (RA). Here, we aimed to evaluate the value of baseline OPG\/TRAIL ratio in predicting clinical and radiological outcomes in patients with early RA in the ESPOIR cohort.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>OPG and TRAIL serum concentrations were assessed in the ESPOIR cohort patients. Patients with definite RA were included in this study. Patients were excluded if they had high erosion score at baseline (&gt;90<jats:sup>th<\/jats:sup> percentile) or received biological therapy during the first 2 years of follow-up. Data were analyzed by univariate analysis and multivariate logistic regression to predict 1-year DAS28 remission and 2-year radiographic disease progression.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>On univariate analysis of 399 patients, OPG\/TRAIL ratio at baseline was significantly lower in patients with than without remission at 1 year (<jats:italic>p<\/jats:italic> = 0.015). On multivariate logistic regression including age, gender, body mass index and DAS28, low OPG\/TRAIL ratio was independently associated with remission at 1 year (odds ratio 1.68 [95 % confidence interval 1.01\u20132.79]). On univariate analysis, high OPG\/TRAIL ratio at baseline was associated with rapid progression of erosion at 2 years (<jats:italic>p<\/jats:italic> = 0.041), and on multivariate logistic regression including age, anti-citrullinated protein antibody positivity and C-reactive protein level, OPG\/TRAIL ratio independently predicted rapid progression of erosion at 2 years.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>OPG\/TRAIL ratio at baseline was an independent predictor of 1-year remission and 2-year rapid progression of erosion for patients with early rheumatoid arthritis. Thus, OPG\/TRAIL ratio could be included in matrix prediction scores to predict rapid radiographic progression. Further confirmation in an independent cohort is warranted.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/s13075-015-0705-3","type":"journal-article","created":{"date-parts":[[2015,7,27]],"date-time":"2015-07-27T10:57:51Z","timestamp":1437994671000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort"],"prefix":"10.1186","volume":"17","author":[{"given":"Rachel","family":"Audo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Daien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Papon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9dric","family":"Lukas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Vittecoq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hahne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Combe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Morel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,29]]},"reference":[{"key":"705_CR1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492\u2013509.","journal-title":"Ann Rheum Dis"},{"key":"705_CR2","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1136\/ard.62.2.120","volume":"62","author":"O Meyer","year":"2003","unstructured":"Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, et al. Anticitrullinated protein\/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis. 2003;62:120\u20136.","journal-title":"Ann Rheum Dis"},{"key":"705_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cyto.2013.04.011","volume":"63","author":"R Audo","year":"2013","unstructured":"Audo R, Combe B, Hahne M, Morel J. The two directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritis. Cytokine. 2013;63:81\u201390.","journal-title":"Cytokine"},{"key":"705_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/ni894","volume":"4","author":"S-E Lamhamedi-Cherradi","year":"2003","unstructured":"Lamhamedi-Cherradi S-E, Zheng S-J, Maguschak KA, Peschon J, Chen YH. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-\/- mice. Nat Immunol. 2003;4:255\u201360.","journal-title":"Nat Immunol"},{"key":"705_CR5","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1084\/jem.191.7.1095","volume":"191","author":"K Song","year":"2000","unstructured":"Song K, Chen Y, G\u00f6ke R, Wilmen A, Seidel C, G\u00f6ke A, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med. 2000;191:1095\u2013104.","journal-title":"J Exp Med"},{"key":"705_CR6","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.2741\/2212","volume":"12","author":"A Anel","year":"2007","unstructured":"Anel A, Bosque A, Naval J, Pineiro A, Larrad L, Alava MA, et al. Apo2L\/TRAIL and immune regulation. Front Biosci J Virtual Libr. 2007;12:2074\u201384.","journal-title":"Front Biosci J Virtual Libr"},{"key":"705_CR7","doi-asserted-by":"publisher","first-page":"15709","DOI":"10.1074\/jbc.M414469200","volume":"280","author":"J Morel","year":"2005","unstructured":"Morel J, Audo R, Hahne M, Combe B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase\/Akt. J Biol Chem. 2005;280:15709\u201318.","journal-title":"J Biol Chem"},{"key":"705_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1006\/bbrc.1999.0252","volume":"256","author":"N Takahashi","year":"1999","unstructured":"Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF\/OPGL\/TRANCE\/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun. 1999;256:449\u201355.","journal-title":"Biochem Biophys Res Commun"},{"key":"705_CR9","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/art.11150","volume":"48","author":"G Schett","year":"2003","unstructured":"Schett G, Redlich K, Hayer S, Zwerina J, Bolon B, Dunstan C, et al. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum. 2003;48:2042\u201351.","journal-title":"Arthritis Rheum"},{"key":"705_CR10","doi-asserted-by":"publisher","first-page":"R108","DOI":"10.1186\/ar4558","volume":"16","author":"R Knevel","year":"2014","unstructured":"Knevel R, de Rooy DPC, Saxne T, Lindqvist E, Leijsma MK, Daha NA, et al. A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis. Arthritis Res Ther. 2014;16:R108.","journal-title":"Arthritis Res Ther"},{"key":"705_CR11","doi-asserted-by":"publisher","first-page":"31601","DOI":"10.1074\/jbc.M706078200","volume":"282","author":"S Vitovski","year":"2007","unstructured":"Vitovski S, Phillips JS, Sayers J, Croucher PI. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem. 2007;282:31601\u20139.","journal-title":"J Biol Chem"},{"key":"705_CR12","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/art.30181","volume":"63","author":"R Audo","year":"2011","unstructured":"Audo R, Calmon-Hamaty F, Baeten D, Bruyer A, Combe B, Hahne M, et al. Mechanisms and clinical relevance of TRAIL-triggered responses in the synovial fibroblasts of patients with rheumatoid arthritis. Arthritis Rheum. 2011;63:904\u201313.","journal-title":"Arthritis Rheum"},{"key":"705_CR13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jbspin.2007.06.001","volume":"74","author":"B Combe","year":"2007","unstructured":"Combe B, Benessiano J, Berenbaum F, Cantagrel A, Daur\u00e8s J-P, Dougados M, et al. The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine. 2007;74:440\u20135.","journal-title":"Joint Bone Spine"},{"key":"705_CR14","first-page":"1792","volume":"22","author":"DM Van der Heijde","year":"1995","unstructured":"Van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp\u2019s method (van der Heijde modification). J Rheumatol. 1995;22:1792\u20136.","journal-title":"J Rheumatol"},{"key":"705_CR15","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1136\/ard.2009.121160","volume":"69","author":"K Visser","year":"2010","unstructured":"Visser K, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Ronday HK, Seys PEH, Kerstens PJSM, et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis. 2010;69:1333\u20137.","journal-title":"Ann Rheum Dis"},{"key":"705_CR16","doi-asserted-by":"publisher","first-page":"R210","DOI":"10.1186\/ar4404","volume":"15","author":"M Meyer","year":"2013","unstructured":"Meyer M, Sellam J, Fellahi S, Kotti S, Bastard J-P, Meyer O, et al. Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Res Ther. 2013;15:R210.","journal-title":"Arthritis Res Ther"},{"key":"705_CR17","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1002\/acr.22078","volume":"65","author":"G Tob\u00f3n","year":"2013","unstructured":"Tob\u00f3n G, Saraux A, Lukas C, Gandjbakhch F, Gottenberg JE, Mariette X, et al. First-year radiographic progression as a predictor of further progression in early arthritis: results of a large national French cohort. Arthritis Care Res. 2013;65:1907\u201315.","journal-title":"Arthritis Care Res"},{"key":"705_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1076-6332(96)80451-X","volume":"3","author":"EJ Halpern","year":"1996","unstructured":"Halpern EJ, Albert M, Krieger AM, Metz CE, Maidment AD. Comparison of receiver operating characteristic curves on the basis of optimal operating points. Acad Radiol. 1996;3:245\u201353.","journal-title":"Acad Radiol"},{"key":"705_CR19","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/1097-0142(1950)3:6<1097::AID-CNCR2820030620>3.0.CO;2-E","volume":"3","author":"SW Greenhouse","year":"1950","unstructured":"Greenhouse SW, Cornfield J, Homburger F. The Youden index: letters to the editor. Cancer. 1950;3:1097\u2013101.","journal-title":"Cancer"},{"key":"705_CR20","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1007\/s10620-013-2851-2","volume":"58","author":"L Nahidi","year":"2013","unstructured":"Nahidi L, Leach ST, Lemberg DA, Day AS. Osteoprotegerin exerts its pro-inflammatory effects through nuclear factor-\u03baB activation. Dig Dis Sci. 2013;58:3144\u201355.","journal-title":"Dig Dis Sci"},{"key":"705_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.mce.2014.06.004","volume":"394","author":"S Bernardi","year":"2014","unstructured":"Bernardi S, Fabris B, Thomas M, Toffoli B, Tikellis C, Candido R, et al. Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Mol Cell Endocrinol. 2014;394:13\u201320.","journal-title":"Mol Cell Endocrinol"},{"key":"705_CR22","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s10495-007-0095-3","volume":"12","author":"S Colucci","year":"2007","unstructured":"Colucci S, Brunetti G, Cantatore FP, Oranger A, Mori G, Pignataro P, et al. The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis. 2007;12:1623\u201332.","journal-title":"Apoptosis"},{"key":"705_CR23","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/jcp.21430","volume":"216","author":"E Chamoux","year":"2008","unstructured":"Chamoux E, Houde N, L\u2019Eriger K, Roux S. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J Cell Physiol. 2008;216:536\u201342.","journal-title":"J Cell Physiol"},{"key":"705_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1196\/annals.1402.011","volume":"1116","author":"G Brunetti","year":"2007","unstructured":"Brunetti G, Oranger A, Mori G, Tamma R, Di Benedetto A, Pignataro P, et al. TRAIL is involved in human osteoclast apoptosis. Ann N Y Acad Sci. 2007;1116:316\u201322.","journal-title":"Ann N Y Acad Sci"},{"key":"705_CR25","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0006-291X(02)00916-6","volume":"296","author":"I Pettersen","year":"2002","unstructured":"Pettersen I, Figenschau Y, Olsen E, Bakkelund W, Smedsr\u00f6d B, Sveinbj\u00f6rnsson B. Tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in human articular chondrocytes in vitro. Biochem Biophys Res Commun. 2002;296:671\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"705_CR26","doi-asserted-by":"publisher","first-page":"R106","DOI":"10.1186\/ar2498","volume":"10","author":"N Courvoisier","year":"2008","unstructured":"Courvoisier N, Dougados M, Cantagrel A, Goupille P, Meyer O, Sibilia J, et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2008;10:R106.","journal-title":"Arthritis Res Ther"},{"key":"705_CR27","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/rheumatology\/kep155","volume":"48","author":"N Vastesaeger","year":"2009","unstructured":"Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology. 2009;48:1114\u201321.","journal-title":"Rheumatology"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0705-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-015-0705-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0705-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0705-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:08:11Z","timestamp":1728922091000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-015-0705-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,29]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12]]}},"alternative-id":["705"],"URL":"https:\/\/doi.org\/10.1186\/s13075-015-0705-3","relation":{},"ISSN":["1478-6354"],"issn-type":[{"type":"electronic","value":"1478-6354"}],"subject":[],"published":{"date-parts":[[2015,7,29]]},"assertion":[{"value":"27 January 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"193"}}